CSC Research & Evidence-Based Practice 2

Question 1

In a randomized controlled trial for a new antiarrhythmic drug, the p-value is 0.03. Which statement best interprets this finding?

Accepted Answer

There is a 3% probability of observing results this extreme if the null hypothesis is true

Answer

A p-value of 0.03 means there is a 3% probability of observing results at least this extreme assuming the null hypothesis is true.

Question 2

A cardiologist wants to evaluate long-term outcomes of TAVR vs. SAVR in high-risk patients. Which study design is most appropriate if randomization is not feasible?

Accepted Answer

Prospective cohort study

Answer

A prospective cohort study follows participants forward in time, allowing assessment of long-term outcomes when randomization is not feasible.

Question 3

Which statistical measure best quantifies the absolute benefit of a cardiac intervention compared to control?

Accepted Answer

Absolute risk reduction

Answer

Absolute risk reduction (ARR) directly quantifies the difference in event rates between treatment and control groups.

Question 4

In a meta-analysis of statin trials, significant heterogeneity (I² = 75%) is detected. What is the most appropriate next step?

Accepted Answer

Perform subgroup analyses to explore sources of heterogeneity

Answer

High I² values indicate substantial heterogeneity; subgroup or sensitivity analyses help identify clinical or methodological sources.

Question 5

A clinical guideline recommends beta-blockers post-MI with a Class I, Level A recommendation. What does Level A indicate?

Accepted Answer

Data derived from multiple randomized controlled trials or meta-analyses

Answer

Level of Evidence A indicates the recommendation is supported by data from multiple randomized controlled trials or meta-analyses.

CSC - Cardiac Subspecialty Certification Exam Practice Test

CSC - Cardiac Subspecialty Certification Exam Practice Test

CSC Research & Evidence-Based Practice 2